# Dupilumab coformulated with berahyaluronidase alfa PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa

> The next catalyst for dupilumab coformulated with berahyaluronidase alfa, sponsored by Sanofi (SNY), is its topline data readout, May to Aug 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | dupilumab coformulated with berahyaluronidase alfa |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Dermatitis Atopic](https://sec-api.dev/indications/dermatitis-atopic) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07919899

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07919899

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)

Calendar months: [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dupilumab coformulated with berahyaluronidase alfa PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa

```bibtex
@misc{secapidev_pdufa_dupilumab_coformulated_with_berahyaluronidase_alfa_20261116,
  title        = {Dupilumab coformulated with berahyaluronidase alfa PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dupilumab_coformulated_with_berahyaluronidase_alfa_20261116","title":"Dupilumab coformulated with berahyaluronidase alfa PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
